Efficacy of oral fenofibrate in management of unconjugated hyperbilirubinemia in the neonate

AUTHOR(s) : Pathak NN, Deka Anupama, Saikia Bidyut
DOI No. :

Introduction: Neonatal jaundice is one of the commonest neonatal problems health care providers encounter every day. Though there are effective treatments like phototherapy and exchange transfusions, there is a need to search for an inexpensive, safe and effective drug therapy for this condition. Objectives were to study the efficacy of oral fenofibrate, a lipid-lowering drug in adults, in the management of unconjugated neonatal hyperbilirubinemia. Materials and methods: Study design: Prospective, double-blinded. Setting: NICU of Silchar Medical College, from July 2017 to June 2018. 100 newborns with unconjugated hyperbilirubinemia divided into 2 groups- control and intervention, 50 in numbers in each group. Efficacy of oral fenofibrate was determined by comparing the control group (receiving phototherapy alone) to the intervention group (fenofibrate+phototherapy) by measuring serum bilirubin level at 0, 12, 24 and 48 hours and the duration of phototherapy. Results: The mean value of total serum bilirubin (TSB) in the fenofibrate group at 24 and 48 hours of starting phototherapy is considerably lower than the control group (p<0.005 and 0.001 respectively). No side effects of fenofibrate observed. Conclusion: Fenofibrate appears to be an effective drug in the management of unconjugated neonatal hyperbilirubinemia. Keywords: Unconjugated; neonatal hyperbilirubinemia; phototherapy.

Registered Office Address:
House No: One, Karmabir Bordoloi Path, Wireless,
Rukmini Nagar, Dispur-06, Assam, India

Mobile: 09435017802
Email: editor@ijhrmlp.org
Website: www.ijhrmlp.org
IJHRMLP is an open-access journal, and the articles published are instantly available to read and use again. The published articles thus can be downloaded, shared, and reused without restriction if the contributing original authors are appropriately cited. Author(s) retain the copyright of their article, with articles licensed to AHRME and the journal following the Creative Commons Attribution License (CC-BY).
Maintain By Prism Infosys